| HUM |
Report |
Adjusted EPS |
BEAT |
pred ~$6.55 vs. cons $6.30 |
MEDIUM |
| HUM |
Report |
Insurance benefit ratio |
IN-LINE |
pred ~91.15% vs. cons 91.25% |
HIGH |
| HUM |
Report |
CenterWell adjusted income from operations |
BEAT |
pred ~$385M vs. cons $360M |
MEDIUM |
| HUM |
Guide |
FY2026 adjusted EPS |
LOWER |
guide ~$9.00 vs. cons $9.45 (FY2026) |
HIGH |
| HUM |
Guide |
FY2026 Insurance benefit ratio |
UNCHANGED |
guide ~92.75% vs. cons 92.70% (FY2026) |
HIGH |
| HUM |
Guide |
FY2026 individual Medicare Advantage membership growth |
BETTER |
guide ~25.0% vs. cons 24.0% (FY2026) |
MEDIUM |
| HUM |
Guide |
Bonus Year 2028 Stars positioning |
UNKNOWN |
guide ~top-quartile target vs. cons ~top-quartile target (BY2028) |
LOW |
| HUM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.5% |
— |
MEDIUM |
| HUM |
Return |
5-day cumulative residual |
+1.5% (FADE) |
A clean benefit-ratio print and EPS beat should drive an initial relief rally, but a reaffirmed ~$9.00 FY2026 EPS floor remains below ~$9.45 consensus and preserves uncertainty around 2027 benefit cuts, retention, and Stars/TBC math. That out-period estimate pressure should limit follow-through after the first-day move. |
MEDIUM |